BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9640221)

  • 1. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience.
    Culine S; Abs L; Terrier-Lacombe MJ; Théodore C; Wibault P; Droz JP
    Eur J Cancer; 1998 Feb; 34(3):353-8. PubMed ID: 9640221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of advanced seminoma: retrospective study of 96 patients].
    Bompas E; Fléchon A; Biron P; Droz JP
    Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VAB-6 as initial treatment of patients with advanced seminoma.
    Stanton GF; Bosl GJ; Whitmore WF; Herr H; Sogani P; Morse M; Golbey RB
    J Clin Oncol; 1985 Mar; 3(3):336-9. PubMed ID: 2579214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
    Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
    J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of metastatic seminoma by chemotherapy.: an experience].
    Komatsubara S; Itoi T; Watanabe M; Kitamura Y; Koike T
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):666-72. PubMed ID: 11109817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual mass after chemotherapy for seminoma: changing concepts of management.
    Herr HW; Bosl G
    J Urol; 1987 Jun; 137(6):1234-5. PubMed ID: 2438431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
    Culine S; Theodore C; Court BH; Perrin JL; Droz JP
    Br J Urol; 1997 Feb; 79(2):258-62. PubMed ID: 9052479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
    Srougi M; Simon SD; de Góes GM
    J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced seminoma: the role of chemotherapy and adjunctive surgery.
    Motzer RJ; Bosl GJ; Geller NL; Penenberg D; Yagoda A; Golbey R; Whitmore WF; Fair WR; Sogani P; Herr H
    Ann Intern Med; 1988 Apr; 108(4):513-8. PubMed ID: 2450500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
    Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of retroperitoneal lymph node dissection in advanced testicular seminoma.
    Kamat MR; Kulkarni JN; Tongaonkar HB; Ravi R
    J Surg Oncol; 1992 Sep; 51(1):65-7. PubMed ID: 1381455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
    Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
    Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of chemotherapy in the treatment of cancer of the testis in adults].
    Le Duc A; Gisselbrecht C; Le Doze H; Mignot L
    Presse Med; 1985 Feb; 14(5):271-5. PubMed ID: 2580297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
    Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
    Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combination chemotherapy including Platidiam in the treatment of malignant testicular tumors.
    Garin AM; Lichinitser MR; Khlebnov AV; Tyulyandin SA
    Neoplasma; 1987; 34(1):85-8. PubMed ID: 2436066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
    Fléchon A; Biron P; Philip I; Blay JY; Droz JP
    Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
    Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
    Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.